TARGETED GENETICS EXPECTS TO RECEIVE $4 MIL. IN NIAID SPIRAT GRANTS
Executive Summary
TARGETED GENETICS EXPECTS TO RECEIVE $4 MIL. IN NIAID SPIRAT GRANTS for AIDS studies being conducted at the Fred Hutchinson Cancer Research Center over a four-year period, the Seattle-based gene therapy R&D firm announced Sept. 1. Targeted Genetics will use the funds to support its research into CD8 cytotoxic T lymphocytes and intracellular vaccines for HIV. The company and the cancer center will receive $1.3 mil. in funding for the first year.